c-Met inhibitors

被引:18
|
作者
Mughal, Anum [1 ]
Aslam, Hafiz Muhammad [1 ]
Sheikh, Asfandyar [1 ,2 ]
Khan, Agha Muhammad Hammad [3 ]
Saleem, Shafaq [1 ]
机构
[1] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan
[2] Pakistan Res Evolut Students Soc, Karachi, Pakistan
[3] Dow Univ Hlth Sci, Sindh Med Coll, Karachi, Pakistan
来源
关键词
c-Met; Tyrosine kinase; Cancer; HEPATOCYTE GROWTH-FACTOR; FACTOR-RECEPTOR; SOMATIC MUTATIONS; KINASE INHIBITORS; ONCOGENE; IDENTIFICATION; PROTOONCOGENE; DISCOVERY; DOMAIN; GENE;
D O I
10.1186/1750-9378-8-13
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio-or immunotherapy
引用
收藏
页数:2
相关论文
共 50 条
  • [21] Recent Patents on the Development of c-Met Kinase Inhibitors
    Xu, Xiangming
    Yao, Lei
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2020, 15 (03) : 228 - 238
  • [22] C-Met, a marker of resistance to EGFR inhibitors in NSCLC
    Engelman, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 22 - 22
  • [23] Synthesis and biological evaluation of Oblongifolin C derivatives as c-Met inhibitors
    Wang, Liping
    Wu, Rong
    Fu, Wenwei
    Lao, Yuanzhi
    Zheng, Changwu
    Tan, Hongsheng
    Xu, Hongxi
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (18) : 4120 - 4128
  • [24] Treatments of NSCLC-PDX with c-MET gene amplification by c-MET inhibitors lead to rapid development of drug resistance
    Yang, Mengmeng
    Song, Xiaoming
    Cai, Jie
    Wang, Youzhu
    Chen, Taiping
    Wery, Jean-Pierre
    Chen, Yiyou
    Li, Henry
    CANCER RESEARCH, 2013, 73 (08)
  • [25] Computational study on novel natural inhibitors targeting c-MET
    Hou, Yuanyuan
    Xie, Haoqun
    Dou, Gaojing
    Yang, Wenzhuo
    Ge, Junliang
    Zhou, Baolin
    Ren, Junan
    Li, Juncheng
    Wang, Jing
    Zhang, Zhiyun
    Wang, Xinhui
    MEDICINE, 2021, 100 (38)
  • [27] Recent Progress in the Development of Small Molecule c-Met Inhibitors
    Lv, Peng-Cheng
    Yang, Yu-Shun
    Wang, Zhong-Chang
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (15) : 1276 - 1288
  • [28] Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
    Eder, Joseph Paul
    Woude, George F. Vande
    Boerner, Scott A.
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2207 - 2214
  • [29] Preclinical profile of novel and potent c-Met kinase inhibitors
    Vakkalanka, Swaroop
    Muthuppalaniappan, Meyyappan
    Govindarajulu, Babu
    Varanasi, Kanthikiran
    Veeraraghavan, Sridhar
    Kuppireddi, Sumalatha
    Viswanadha, Srikant
    Dhanapalan, Nagarathnam
    Bhavar, Prashant
    CANCER RESEARCH, 2012, 72
  • [30] Preclinical profile of novel and potent c-Met kinase inhibitors
    Vakkalanka, S.
    Muthuppalaniappan, M. P.
    Babu, G.
    Kuppireddi, S.
    Viswanadha, S.
    Veeraraghavan, S.
    Varanasi, K. K. V. S.
    EJC SUPPLEMENTS, 2010, 8 (07): : 108 - 108